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Abstract  
Aims:To evaluate the early cancer control rates, morbidity and mortality in men undergoing 
radical retropubic prostatectomy (RRP) for clinically localized adenocarcinoma prostate. 
Methods:Patient’s characteristics, operative data, progressive-free survival rates, morbidity 
and mortality were analyzed for 23 men with clinical T1-2 prostate cancer who underwent 
surgery with an intent to treat by RRP between December 1997 to July 2001. 
Results:Patient’s mean age was 63±6.2 years (range 51 to 76 years) with American Society 
of Anesthesiology (ASA) status I in 4%, II in 65% and Ill in 31%. Two third of the patients 
had lower urinary tract obstructive symptoms, followed by hematuria (9%) and back pain 
(4%). Clinical stages were Tib in 4%, Tic in 9%, T2a in 17%, T2b in 22% and T2c in 48% of 
the patients. Mean pre-operative serum prostate specific antigen (PSA) was 25 ±29 ng/ml 
(1.110 99.3). Bilateral pelvic lymphnode disection(PLND) and RRP was performed in 20 
cases (nerve-sparing RRP 5 cases). In 3 cases with gross lymph node metastasis at frozen 
section, only bilateral orchidectomy was done. The mean operative time was 270 ±65 
minutes and mean blood loss was 1097 ±654 mIs. Packed cell transfusions were nil in 26%, 
1-2 units in 44%, 3-4 units in 26% and 5 units in 4% of the patients who underwent RRP. 
The mean length of hospital stay was 10.2 ± 1 days. Out of 20 patients who underwent RRP, 
65% of tumors were confined to the specimen, 20% had seminal vesicle invasion and 15% 
had nodal metastasis. There was no pen-operative mortality while 2 patients developed 
epididymo-orchitis and I had myocardial ischemia (without infarction). Overall 87% of the 
patients were fully continent and 13% had mild to moderate stress urinary incontinence. The 
mean time of return of continence was 11.5 ± 11.6 weeks. Two of the 3 patients (66%) with 
follow up information and having undergone nerve-sparing RRP are potent. 
At a mean follow up of 19.4 ± 13 months (range 3-45 months), 20 of 23 total patients (87%) 
and 17 of 20 RRP patients (85%) remained free of disease recurrence with PSA 0.4 ng/ml. 
Conclusion:Our early results confirm the excellent potential for cancer control and low 
morbidity of radical prostatectomy for men with localized prostate cancer. These results are 
in conformity with the vast Western experience. Long-term results will be provided (JPMA 
52:200; 2002). 
Introduction  
Three to four decades ago, prostate cancer ranked low as a cause of morbidity and mortality 
for the Western males1-3. Today, it represents the most commonly diagnosed related death4. It 
is estimated that during the year 2001, it would account for 31% of newly diagnosed cancers 
and 11% of cancer-related deaths in American men4. 
This dramatic increase in the disease burden has been attributed to availability of refined 
methods of diagnosis (regular digital rectal examination, prostate specific antigen blood test, 
transrectal ultrasound, systematic prostatic biopsy), increased life expectancy with an ever 
aging population, as well as, to enhanced awareness about the disease in Western 
community5,6. 
The disease burden however, remains remarkably different between the Eastern and the 
Western countries7. The age-adjusted prostate cancer mortality rates from China, Japan and 
other Eastern countries appears less threatening than those reported from Europe and USA4. 
While the exact reasons remain unclear, genetic, environmental and dietary factors have been 
implicated8. Interestingly despite widely variable incidence of clinically detectable cases 
between different populations, autopsy studies from around the world show no variation in 
the prevalence of small latent cancers in men who die with no clinical evidence of prostate 
cancer9-13. 
Recent data from some of the Asian countries indicates a rapid increase in the incidence and 
mortality of prostate cancer14-16. Between 1985 and 1997, a 230% increase in prostate cancer 
mortality has been observed in Japanese men14. This change resembles the earlier trends of 
Western countries and is attributed to an aging population, environmental! dietary factors and 
better diagnostic methods. Since mortality from prostate cancer increases more rapidly with 
age than any other cancer and life expectancy in Asian men, like those in the west, is 
increasing, the incidence and mortality from prostate cancer is likely to increase significantly 
over time17,18. Thus, if prostate cancer is likely to become a major health problem for Asian 
men it is highly desirable that appropriate measures be undertaken to diagnose and manage 
this disease effectively. 
While the optimal treatment of prostatic cancer is debatable, radical prostatectomy has 
evolved as an established method to treat clinically localized prostate cancer in appropriately 
selected men. The major advantage of radical surgery is the high probability that the cancer 
can be completely removed, especially if it is confined to the prostate pathologically19. 
Fifteen-year cancer specific survival rates range from 86% to 93%20. With refmements in 
surgical technique and improved perioperative care, the morbidity of the operation has 
markedly decreased and the 30-day mortality in contemporary literature is less than 0.3%20,21 
Similarly, blood transfusion rates, mean hospital stay and cost of care has also decreased20,21. 
The main long-term complications relate to potency and continence. While significant 
urinary incontinence and anastamotic strictures are infrequent, post-operative erectile 
dysfunction still remains as a major morbidity of this operation. 
There is limited Asian data on surgical treatment for localized prostate cancer22-24. We, 
herein, present our early results of radical retropubic prostatectomy from a single institution 
in men with clinical stages Ti to T2 prostate cancer. 
Patients and Methods  
Between December 1997 and June 2001, 23 men with clinical stage TI-2NxMo prostatic 
adenocarcinoma underwent PLND with or without RRP at The Aga Khan University 
Hospital. Clinical stages were assigned preoperatively using the TNM system. In addition to 
routine evaluation, all patients had digital rectal examination (DRE) and serum prostate 
specific antigen (PSA) estimation, (Abbott Laboratories, Chicago, IL, IMX assay) whilst 
most had transrectal ultrasonography (TRUS) prior to surgery. Patients with clinical 
suspicion of extraprostatic extension of cancer (T3 lesions) were not considered for radical 
prostatectomy. The PSA levels were obtained prior to DRE or manipulation or at least 3 
weeks after a prostatic biopsy or manipulation. A PSA level of 4.0 ng!ml or more was 
considered an abnormal result and the results obtained closest to the surgery were used as 
preoperative PSA values. Distant metastases were excluded by a normal radionuclide bone 
scan and a CT scan of the abdomen and pelvis. 
Standard pelvic lymph node dissection and modified anatomical radical retropubic 
prostatectomy was performed21. We routinely perform frozen section analysis of the pelvic 
lymph nodes and those who had gross metastasis did not undergo radical prostatectomy, 
instead bilateral orchidectomy was carried out. In patients who were potent preoperatively, 
nerve-sparing radical prostatectomy was performed when neurovascular bundles were 
intraoperatively assessed to be grossly uninvolved by cancer. In patients with palpable tumor 
in close proximity of neurovascular bundle, the ipsilateral bundle was excised. Details of the 
operative findings, surgical procedure, intra and post-operative complications, blood loss and 
transfusions were recorded. Patients were discharged with indwelling Silicone catheter to be 
removed at 2 weeks in the outpatient clinic. 
All prostatic biopsy specimen, whether obtained at our university or outside, were reviewed 
at our pathology department to confirm the presence of malignancy. The radical 
prostatectomy specimens were fixed en bloc in formaldehyde and painted on the outside with 
India ink, then sectioned. The histological grades (Gleason’s primary and secondary grades) 
were recorded and the presence of seminal vesicle invasion, lymph nodes metastasis and 
tumor extension outside the surgical specimen was noted. All lymph nodes were examined 
for metastasis. Based on these findings, the pathologic stage was assigned according to the 
TNM system. 
Following initial postoperative visits, the patients were followed with DRE and serum PSA 
levels, more or less, every 3 months for 1 year and subsequently every 6 months. Progression 
of the disease was defined as either clinical evidence of disease recurrence or biochemical 
recurrence with progressively rising PSA, with levels >0.4 ng/ml. At each visit, urinary 
continence, potency, development of any complication and additional treatments undertaken 
were noted. 
Results 
The mean age was 63 ± 6.2 years (median 64 years, range 51 - 76). ASA classification 
showed that 4% of the patients belonged to class I, 65% to class II and 31% to class III. Most 
patients were clinically symptomatic with 10 (44%) presenting with lower urinary tract 
obstructive symptoms (Table 1). 
 Only 40 (17%) of the patients were asymptomatic and were diagnosed with prostate cancer 
following routine PSA testing. 
On DRE, 3 patients (13%) had normal prostate while 20 (87%) had abnormal findings (Table 
2). 
 
This included 4 with a unilateral nodule involving less than half of the lobe (T2a lesion), 5 
with a unilateral nodule involving more than half of the lobe (T2b lesion), and 11 with 
bilaterally palpable nodules (T2c lesion). Patients with clinical T3 lesions were not 
considered for radical surgery. 
Serum PSA levels were found to be elevated above normal in all cases except in one patient 
who was on hormonal therapy for 2 months following transuretheral resection of prostate 
(TURP) done outside. He was taken off the hormonal therapy prior to radical prostatectomy. 
The mean PSA was 25 ± 29, (median PSA = 13.7, range 1.1 -99). PSA ranges are given in 
Table 2. 
All patients had a negative bone scan and CT scan of the abdomen and pelvis for metastatic 
disease. In one case with serum PSA of 84 ng/ml, MRI bone survey and trephine bone 
marrow biopsy was done and was also negative for metastasis. 
Five patients had evidence of nodal metastasis at frozen section. In 3 with gross metastasis 
RPR was abandoned and bilateral orchidectomy was carried out. While in 2 who had micro 
metastasis, standard RRP and bilateral orchidectomy was performed. The remaining 18 
patients with no nodal metastasis underwent standard RRP (Table 3). 
 
The decision to perform nerve-sparing RRP was based on pre-operative potency status and 
intra-operative assessment of proximity of the cancer to the neuro-vascular bundles (NVB). 
Of 20 cases, who had RRP 5 patients (25%) had complete bilateral NVB preservation and 7 
(35%) had partial NVB preservation. In 8 patients (40%) bilateral NVB resection had to be 
performed in order to achieve a wide clearance margin. 
Table 3 shows the operative time, estimated blood loss, transfusions, and patient’s length of 
stay. Overall, 74% of all cases (17 of 23) and 85% of RRP cases (17 of 20) received 
perioperative blood transfusion. The mean transfusion requirement was 2.2 ±, 1.5 packed red 
cell units per patient. In RRP cases, 15% had no transfusions while 50% received 1 - 2 units, 
30% had 3 - 4 units and 5% had 5 units of packed cell transfusions. 
There was no mortality. Perioperative complications were observed in 3 patients (13%) 
including 1 case (4%) of myocardial ischaemia with no infarction and 2 cases (9%) who 
developed epididymo-orchitis. 
Overall, 87% patients (20 of 23) are fully continent while 13% have mild to moderate stress 
urinary incontinence. Amongst 20 patients who underwent RRP, 85% (17 of 20) are fully 
continent and 15% (3 of 20) have mild to moderate stress urinary incontinence at> 6 months 
after surgery requiring I to 2 pads per day (Table 4). 
 The overall pathological staging (TNM) and grading (Gleason grading system) is shown in 
Table 5. 
 
At a mean follow up of 19.4 ± 13 months (median 15, range 3 - 45), 20 of 23 total patients 
(87%) and 17 of 20 patients who had RRP (85%) remain free of cancer sections revealed 
micrometastasis in pelvic lymph nodes. 
In patients who underwent RRP and are continent, the mean time to return to fully continent 
status was 11.5 ±11.6 weeks (median 8; range 2 - 40 weeks). The return of continence in 
patients with previous TURP was 10 ± 2 weeks compared with 12 ±. 13 weeks in those with 
no previous prostatic surgery. Three patients (15%) developed anastamotic strictures; 2 
underwent optical urethrotomy and one had urethral dilation. The follow up information 
about potency status is available in 3 of 5 cases who had bilateral NVB preservations. Two of 
these 3 patients (66%) are potent. 
recurrence with PSA levels 0.4 ng/ml. This is with no further cancer-related treatment except 
for adjuvant external beam radiation therapy in 2 cases administered on the basis of adverse 
histopathology. All 3 patients who failed surgical treatment (PSA >0.4ng/ml) had high-grade 
cancer with seminal vesicle invasion. 
Discussion  
Prostate cancer remains an important cause of morbidity and mortality in middle aged and 
elderly males. While the disease burden is far more pronounced in the western world4, recent 
data indicates a significant increase in the age-adjusted incidence and mortality rates in many 
Asian countries14-16. Unfortunately a substantial percentage of Asian men still present with 
regionally advanced and metastatic cancer, which remains incurable25. This can be compared 
to the earlier pattern of disease in the western world. In the pre-PSA era of the 1970s, only 
50% of the cancers detected were clinically organ-confmed (clinical stage A and B, 
Whitmore and Jewett Classification), and 25-30% had metastases at diagnosis26,27. The last 3 
decades, however, witnessed major refinements in the diagnosis and treatment of prostate 
cancer. By utilizing the improved diagnostic techniques of regular DRE, serum PSA, 
transrectal ultrasound and systematic biopsies in select cases, over 90% of cancers currently 
diagnosed in screening studies are clinically organ-confmed and 70% of those are 
pathologically organ confined6,28. Similarly, in non screened populations, 70% of cancers 
detected by DRE or PSA are clinically organ-confined (Tl-2,NxMo) and about half of those 
treated surgically are pathologically confined to the prostate (pTl-2,NoMo)29. The incidence 
of pelvic lymph node metastasis has decreased to 5-7% in recent series of radical 
prostatectomy30,31. This demonstrates a remarkable stage migration with an increasing 
percentage of localized cancers being diagnosed in younger men, amenable to potentially 
curative treatment. 
Similarly, marked advancements have taken place in improving the techniques of potentially 
curative treatment options of radical prostatectomy and radiation therapy. Reiner and Walsh32 
described the anatomical RRP with delineation and control of dorsal venous complex. This 
led to marked reduction in intraoperative blood loss, which used to be a major morbidity of 
this operation. Subsequently, Walsh and Donker33 defined the anatomy of the cavernosal 
nerves and pelvic plexus. With nerve-sparing operation34, it has become possible to preserve 
sexual function in a substantial percentage of appropriately selected patients without 
compromising cancer control. A much improved understanding of the anatomy of striated 
urethral sphincter has also led to modifications in surgical technique with subsequent 
reduction in the frequency of postoperative urinary incontinence.35 
The major advantage of surgery in the treatment of clinically localized prostate cancer is the 
high probability that the cancer would be completely removed, especially if it is confined 
within the prostate pathologically19,36. In modern series, 80% of patients with clinical stage 
Tl-2, NxMo prostate cancer treated with radical prostatectomy have no evidence of 
progression at 5 years as assessed by PSA estimation and 70% are free of progression at 10 
years21. Radical surgery, however, has its associated morbidity and mortality though 
markedly decreased than before. Postoperative mortality is rare, accounting for 0.2% to 0.7% 
in large contemporary series. Serious morbidity (myocardial infarction, pulmonary 
embolism, pneumonia) occurs in 2 to 3% and the need for a blood transfusion is in about 
10% cases37. Therefore, the risk-benefit analysis is crucial while formulating treatment plan 
for an individual patient with prostate cancer. 
Radical prostatectomy should be considered for men with clinically localized prostate cancer 
if they are in good general health and have a life expectancy of 10 years or longer. The risk 
of spread of cancer with conservative treatment needs to be assessed against the potential 
side effects of radical surgery. Thus, the most important factors’ that influence the risk-
benefit analysis include the age and general health of the patient, the extent of cancer 
involvement (PSA, grade, stage) and the potential of cure and complications with surgical 
treatment20. 
Our small series confirms the excellent cancer control potential of this operation, although 
the patients need a longer follow-up. The effective management of prostate cancer in a 
developing country, however, remains far from acceptable. For a variety of reasons, there are 
no concerted efforts to diagnose this cancer at an earlier stage. Thus, most patients in 
Pakistan still present with locally advanced or metastatic cancer and cannot be considered for 
curative treatment. Even, in our select group of Ti -2 cancer cases, most patients had a 
significant disease burden with bilateral prostatic nodularity (cT2c stage) present in 48% of 
cases. Only 9% of the cases in our series were Tic cancers, (elevated PSA and normal DRE). 
This contrasts remarkably with the western series where Tic cancers account for upto half of 
all treated cases.19,34,36 In our early experience, the blood transfusion rate and the length of 
stay is higher than the contemporary series, 19,34,36 which hopeflully would improve with 
increasing experience. Our cancer control rate, return of urinary continence and potency data 
compares favorable with the contemporary data.19,34,36,37 A higher than expected percentage 
of our patients developed anastomotic strictures, which could be related to previous TURP in 
one of three such cases. Despite most cases having an ASA II and III status, we fortunately 
did not encounter any serious complications or perioperative mortality. 
In conclusion, radical prostatectomy appears to be generally safe and can effectively 
eradicate cancer in a large proportion of patients. With refinements in surgical technique and 
improved anesthesia facilities, the surgery related morbidity and mortality has markedly 
decreased. We recommend radical prostatectomy as a potentially curative option in select 
men with localized prostate cancer. 
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